Financial Survey: Gamida Cell (GMDA) vs. Its Rivals

Share on StockTwits

Gamida Cell (NASDAQ: GMDA) is one of 255 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Gamida Cell to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Profitability

This table compares Gamida Cell and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A N/A N/A
Gamida Cell Competitors -4,789.27% -257.83% -37.30%

Insider and Institutional Ownership

1.7% of Gamida Cell shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Biotechnology” companies are owned by institutional investors. 21.5% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Gamida Cell and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gamida Cell N/A -$52.93 million -1.09
Gamida Cell Competitors $47.41 million -$65.11 million -21.74

Gamida Cell’s competitors have higher revenue, but lower earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Gamida Cell and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 5 0 3.00
Gamida Cell Competitors 372 1484 3800 83 2.63

Gamida Cell presently has a consensus price target of $19.40, suggesting a potential upside of 68.70%. As a group, “Biotechnology” companies have a potential upside of 2.98%. Given Gamida Cell’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Gamida Cell is more favorable than its competitors.

Summary

Gamida Cell beats its competitors on 8 of the 12 factors compared.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

-$0.29 Earnings Per Share Expected for Transocean LTD  This Quarter
-$0.29 Earnings Per Share Expected for Transocean LTD This Quarter
salesforce.com, inc.  Chairman Sells $1,615,100.00 in Stock
salesforce.com, inc. Chairman Sells $1,615,100.00 in Stock
Insider Selling: Essex Property Trust Inc  Insider Sells 2,682 Shares of Stock
Insider Selling: Essex Property Trust Inc Insider Sells 2,682 Shares of Stock
Clearwater Paper  Downgraded by Zacks Investment Research
Clearwater Paper Downgraded by Zacks Investment Research
Nice  Hits New 12-Month High at $121.44
Nice Hits New 12-Month High at $121.44
Cisco Systems  Hits New 52-Week High at $53.94
Cisco Systems Hits New 52-Week High at $53.94


Leave a Reply

© 2006-2019 Ticker Report